Product

zilganersen

Aliases

ION373

1 clinical trial

1 indication

Indication

Alexander Disease

Clinical trial

A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered Zilganersen (ION373) in Patients With Alexander Disease

Status: Recruiting, Estimated PCD: 2025-03-01